相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951
Martin J. van den Bent et al.
CLINICAL CANCER RESEARCH (2011)
Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951
Ahmed Idbaih et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis
Julien Laffaire et al.
NEURO-ONCOLOGY (2011)
Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective
Martin J. van den Bent
ACTA NEUROPATHOLOGICA (2010)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Houtan Noushmehr et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Martin J. van den Bent et al.
CLINICAL CANCER RESEARCH (2010)
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
Michael Brada et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
Takuya Watanabe et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up
Linda Douw et al.
LANCET NEUROLOGY (2009)
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951
Mathilde C. M. Kouwenhoven et al.
NEURO-ONCOLOGY (2009)
Analysis of the IDH1 codon 132 mutation in brain tumors
Joerg Balss et al.
ACTA NEUROPATHOLOGICA (2008)
Anaplastic oligodendroglial tumors: Refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402
Caterina Giannini et al.
BRAIN PATHOLOGY (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy:: Results of a European organisation for research and treatment of cancer randomized clinical trial
Martin J. B. Taphoorn et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Survey of treatment recommendations for anaplastic oligodendroglioma
Lauren E. Abrey et al.
NEURO-ONCOLOGY (2007)
Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034
M. J. Van Den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome
Johan M. Kros et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2007)
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment
Mathilde C. M. Kouwenhoven et al.
EUROPEAN JOURNAL OF CANCER (2006)
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Treating Individuals 1 - External validity of randomised controlled trials: To whom do the results of this trial apply?'
PM Rothwell
LANCET (2005)
Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy - A phase II study
AA Brandes et al.
CANCER (2004)
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features
MJ van den Bent et al.
CANCER (2003)
分享论文
